Clinical Trials Logo

Hyperbilirubinemia, Neonatal clinical trials

View clinical trials related to Hyperbilirubinemia, Neonatal.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01330667 Withdrawn - Clinical trials for Hyperbilirubinemia, Neonatal

Effect of Early Limited Formula on Total Serum Bilirubin Among Newborns With Hyperbilirubinemia

Start date: July 2015
Phase: N/A
Study type: Interventional

The investigators propose to conduct an exploratory pilot study, enrolling 30 exclusively breastfeeding newborns 36-96 hours of age, whose Total Serum Bilirubin (TSB) is within 0.1-3 mg/dl of the American Academy of Pediatrics (AAP)-recommended treatment thresholds for Phototherapy (PT). These newborns will be randomly assigned to receive either 10 cc extensively hydrolyzed formula following each breastfeeding using cup, spoon or syringe, or to continue exclusive breastfeeding. Infants will be followed at 1, 2, 3 and 6 months to assess breastfeeding duration and use of formula and complementary foods. Our hypothesis is that limited, small amounts of formula administered without a bottle immediately following breastfeeding might reduce the incidence of severe hyperbilirubinemia among newborns at increased risk of TSB exceeding AAP-recommended thresholds for beginning phototherapy.

NCT ID: NCT00917007 Withdrawn - Neonatal Jaundice Clinical Trials

Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis

Start date: June 2009
Phase:
Study type: Observational

The purpose of this research study is to more accurately measure the amount of true red blood cell breakdown (hemolysis) in newborn babies with potentially problematic blood type mismatch with their mothers (ABO incompatibility), and to examine how the true level of red blood cell destruction relates to other laboratory tests obtained in newborns with jaundice. A better understanding of the true amount of red blood cell destruction that is caused by blood type mismatch, as well as how it relates with other laboratory tests ordered for ABO incompatibility and red blood cell destruction, would help avoid unnecessary testing, treatment and prolonged hospital stays in such babies.